GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (FRA:8EV) » Definitions » Sale Of Investment

TheraCryf (FRA:8EV) Sale Of Investment : €0.00 Mil (TTM As of Sep. 2023)


View and export this data going back to 2018. Start your Free Trial

What is TheraCryf Sale Of Investment?

TheraCryf's sale of investment for the six months ended in Sep. 2023 was €0.00 Mil. It means TheraCryf gained €0.00 Mil from selling investments. TheraCryf's sale of investment for the trailing twelve months (TTM) ended in Sep. 2023 was €0.00 Mil.

Compared with last quarter (€0.00 Mil in Mar. 2023 ), TheraCryf gained the same money from selling investments in Sep. 2023 (€0.00 Mil).


TheraCryf Sale Of Investment Historical Data

The historical data trend for TheraCryf's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf Sale Of Investment Chart

TheraCryf Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1.77 5.12

TheraCryf Semi-Annual Data
Mar13 Mar14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

TheraCryf Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TheraCryf Sale Of Investment Related Terms

Thank you for viewing the detailed overview of TheraCryf's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


TheraCryf (FRA:8EV) Business Description

Traded in Other Exchanges
Address
Congleton Road, Suite 24G13- Block 24, Alderley Park, Nether Alderley, GBR, SK10 4TG
Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage.

TheraCryf (FRA:8EV) Headlines

No Headlines